These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 20189796)

  • 1. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
    Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
    Landi MT; Kanetsky PA; Tsang S; Gold B; Munroe D; Rebbeck T; Swoyer J; Ter-Minassian M; Hedayati M; Grossman L; Goldstein AM; Calista D; Pfeiffer RM
    J Natl Cancer Inst; 2005 Jul; 97(13):998-1007. PubMed ID: 15998953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.
    Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K
    Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain.
    de Torre C; Garcia-Casado Z; Martínez-Escribano JA; Botella-Estrada R; Bañuls J; Oliver V; Mercader P; Azaña JM; Frias J; Nagore E
    Melanoma Res; 2010 Aug; 20(4):342-8. PubMed ID: 20539244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
    Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
    J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
    Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
    Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.
    Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM
    Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanocortin 1 receptor (MC1R) variants in high melanoma risk patients are associated with specific dermoscopic ABCD features.
    Quint KD; van der Rhee JI; Gruis NA; Ter Huurne JA; Wolterbeek R; van der Stoep N; Bergman W; Kukutsch NA
    Acta Derm Venereol; 2012 Nov; 92(6):587-92. PubMed ID: 22965007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population.
    Brudnik U; Branicki W; Wojas-Pelc A; Kanas P
    Exp Dermatol; 2009 Feb; 18(2):167-74. PubMed ID: 18637131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MC1R, ASIP, TYR, and TYRP1 gene variants in a population-based series of multiple primary melanomas.
    Helsing P; Nymoen DA; Rootwelt H; Vårdal M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2012 Jul; 51(7):654-61. PubMed ID: 22447455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma.
    Kanetsky PA; Rebbeck TR; Hummer AJ; Panossian S; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Culver HA; Zanetti R; Gallagher RP; Dwyer T; Busam K; From L; Mujumdar U; Wilcox H; Begg CB; Berwick M
    Cancer Res; 2006 Sep; 66(18):9330-7. PubMed ID: 16982779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk.
    Debniak T; Scott R; Masojc B; Serrano-Fernández P; Huzarski T; Byrski T; Debniak B; Górski B; Cybulski C; Medrek K; Kurzawski G; van de Wetering T; Maleszka R; Kładny J; Lubinski J
    Int J Cancer; 2006 Dec; 119(11):2597-602. PubMed ID: 16988943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
    Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
    BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients.
    Bassoli S; Maurichi A; Rodolfo M; Casari A; Frigerio S; Pupelli G; Farnetani F; Pelosi G; Santinami M; Pellacani G
    Exp Dermatol; 2013 Jun; 22(6):411-6. PubMed ID: 23711066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.